Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule.
Numico G, Russi EG, Vitiello R, Sorrentino R, Colantonio I, Cipolat M, Taglianti RV, Pelissero A, Fea E, Granetto C, Di Costanzo G, Gasco M, Garrone O, Occelli M, Merlano M. Numico G, et al. Among authors: fea e. Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):731-7. doi: 10.1016/j.ijrobp.2006.05.059. Int J Radiat Oncol Biol Phys. 2006. PMID: 17011449
Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score.
Numico G, Occelli M, Russi EG, Silvestris N, Pasero R, Fea E, Granetto C, Di Costanzo G, Colantonio I, Gasco M, Garrone O, Polla V, Merlano MC. Numico G, et al. Among authors: fea e. Support Care Cancer. 2011 Nov;19(11):1823-30. doi: 10.1007/s00520-010-1024-5. Epub 2011 May 11. Support Care Cancer. 2011. PMID: 21560032
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; BEBYP Study Investigators. Masi G, et al. Among authors: fea e. Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18. Ann Oncol. 2015. PMID: 25600568 Free article. Clinical Trial.
Heterogeneity of colon cancer: from bench to bedside.
Merlano MC, Granetto C, Fea E, Ricci V, Garrone O. Merlano MC, et al. Among authors: fea e. ESMO Open. 2017 Aug 22;2(3):e000218. doi: 10.1136/esmoopen-2017-000218. eCollection 2017. ESMO Open. 2017. PMID: 29209524 Free PMC article. Review.
Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide.
Merlano MC, Merlotti AM, Licitra L, Denaro N, Fea E, Galizia D, Di Maio M, Fruttero C, Curcio P, Vecchio S, Russi EG, Corvò R. Merlano MC, et al. Among authors: fea e. Clin Transl Radiat Oncol. 2018 Aug 13;12:47-52. doi: 10.1016/j.ctro.2018.08.001. eCollection 2018 Aug. Clin Transl Radiat Oncol. 2018. PMID: 30186977 Free PMC article.
38 results